Darifenacin Hydrobromide

Slides:



Advertisements
Similar presentations
Module II The Basics of the Brain, the Body and Drug Actions
Advertisements

New drugs and the management of incontinence Stephen Mark.
Urinary Incontinence Kieron Durkan GPST 1.
Pharmacokinetics as a Tool
Objectives Define urinary incontinence
The Overactive Bladder
Dr Mark Donaldson Consultant Physician in Geriatric Medicine
Overactive Bladder: Diagnosis and Treatment Chase Kenyon Sovell, MD Urology Associates May 30 th, 2007 Pearls of Plumbing Seminar.
Pharmacotherapy in the Elderly Judy Wong
ANTICHOLINERGIC DRUGS Pharmacology Department
Treatment of Overactive Bladder — What is Best? Presented by (insert name of presenter here)
“URINARY INCONTINENCE IN WOMEN 2013” NICE guidelines implementation in Primary Care Tony Smith Urogynaecologist St Mary’s HospitalAnson Medical CentreManchester.
Urinary Incontinence Victoria Cook
Drugs and Urinary Incontinence
Mosby items and derived items © 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 7 Opioid (Narcotic) Analgesics and Antagonists.
Urinary Incontinence Dr Asso F.A.Amin MRCP(UK),MRCGP,MRCPE.
Nursing approaches for urgency and Urge Incontinence
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 14 Muscarinic Agonists and Antagonists.
Urinary Incontinence in women. Urinary incontinence Stress – involuntary leakage of urine on effort, sneezing or coughing Urgency – involuntary leakage.
Continence in the very aged Mark Weatherall University of Otago, Wellington.
ANTICHOLINERGIC DRUGS Prof. Alhaider Pharmacology Department Prof. Hanan Hagar Pharmacology Department.
Anticholinergic drugs Prof. Alhaider 1433 H Are drugs that block cholinergic receptors. Anticholinergic drugs.
MANAGING GENITO-URINARY PROBLEMS THE ROLE OF THE PHARMACIST Dr Rebekah Moles Faculty of Pharmacy
1 One Year Post-Exclusivity Adverse Event Review: Tolterodine Pediatric Advisory Committee Meeting June 29, 2005 Lawrence Grylack, MD Medical Officer Division.
Anticholinergics in COPD presented by: Soha Ragab Moselhy group 2.
ANTICHOLINERGIC DRUGS Prof. Alhaider Pharmacology Department Prof. Hanan Hagar Pharmacology Department.
King Saud University College of Nursing Fundamentals of Nursing URINARY ELIMINATION.
Urinary Incontinence (UI) Management in Family Practice References: Can Fam Physician 2003;49: Can Fam Physician 2003;49: SOGC Clinical.
Bioavailability Dr Mohammad Issa.
Keeping the right patients away from hospital
Sharon English Urologist Christchurch
門診處方討論 Fludrocortisone (Florinef) 用於 Orthostatic hypotension 報告者 : 黃玉鈴
PHARMACOKINETICS Part 3.
Over active bladder drug treatment Mark Weatherall University of Otago Wellington.
ECONOMIC EVALUATION OF THE USE OF OXYBUTYNIN, TOLTERODINE AND SOLIFENACIN IN PATIENTS WITH OVERACTIVE BLADDER February 6, 2009.
ANTICHOLINERGIC DRUGS
ANTICHOLINERGIC DRUGS Prof. Alhaider Pharmacology Department Prof. Hanan Hagar Pharmacology Department.
Update On OAB Joon Chul Kim The Catholic University of Korea.
PROF. Rosita Aniuliene LITHUANIAN UNIVERSITY OF HEALTH SCIENCES President of Lithuanian Association of Urogynecology.
Prescribing information is available at this meeting MODULE 3 TREATMENT OPTIONS AND EXPECTATIONS 1 DET 808.
Pharmacokinetics of Drug Absorption Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University.
Metabolic Stability Lee, Sang-Hwi. -2- Overview Metabolism is the enzymatic modification of compounds to increase clearance. It is a determinant.
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
Donepezil. Donepezil Generic name: Donepezil. Brand name: Aricept. Chemistry: Donepezil hydrochloride is a piperidine derivative. It is a white crystalline.
MD. HAMZA ALBEE ASHANIA AKHTER TASNOVA NOWRIN KANZIL MAULA MOU RUBAIYAT ISLAM MONA AFRIN A RAHMAN AIRIN NAHER SHAGUFTA JASMIN SUBI.
PPS 946 Dr Piascik 1/21/16. At the end of this session, students should be able to:  Describe the types of urinary incontinence  Describe the non-pharmacologic.
URINARY INCONTINENCE Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara.
Cimetidine.
Copyright © 2016, 2013, 2010 by Saunders, an imprint of Elsevier Inc. All rights reserved. Chapter 14 Muscarinic Agonists and Antagonists.
โดย เภสัชกรณัฐวุฒิ จรีบุญ สมโภช. OAB affects 33 million people in the United States (17% of American adults) more common in women and in older people.
Urinary incontinence (UI) Niazy B Hussam Aldin PhD Clinical Pharmacy
A COMPARATIVE ANALYSIS OF DIFFERENT BRANDS OF TIZANIDINE HCL.
Metreleptin Drugbank ID :DB09046
Drug Discovery &Development
Current Management of OAB
Antimuscarinic drugs for overactive bladder
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
Pharmacologic therapy of UI
International Neurourology Journal 2012;16:
Management of Male OAB; Current Status in Japan
Drugs for the treatment of irritable bowel syndrome (IBS)
OB,GYN / Fellowship of Pelvic Floor
Bladder Dysfunction Associated With Parkinson’s Disease
School of Pharmacy, University of Nizwa
School of Pharmacy, University of Nizwa
Cholinergic Antagonist
Cholinergic Antagonist
Volume 54, Issue 4, Pages (October 2008)
Philip Toozs-Hobson, Pallavi Latthe  European Urology Supplements 
Intro to Neuromuscular blocking agents
Presentation transcript:

Darifenacin Hydrobromide

Overactive Bladder OAB Frequency Urination at night Urgency 8 or more visits to the toilet per 24 hours Urination at night • 2 or more visits to toilet during sleeping hours Urgency Sudden, strong desire to urinate Urge Incontinence Sudden & involuntary loss of urine Among the symptoms of OAB, frequency is defined as eight or more visits to the toilet per 24-hour period, two or more of which may be during the night. Urgency is defined as a sudden, strong desire to urinate. Urge incontinence is defined as the sudden, involuntary loss of urine. OAB 2

Muscarinic receptors

Treatment Antimuscarinic drugs First-generation----e.g Oxybutynin (primarily selective) Second-generation---- e.g Tolterodine (balanced selective M2/M3) New drugs----e.g Darifenacin (M3 selective receptor antagonis)

Darifenacin hydrobromide ----A potent and competitive M3 selective receptor antagonist a white to almost white, crystalline powder. Brand name : Emselex Synonyms: (S)-2-{1-[2-(2,3-Dihydrobenzofuran-5-yl)Ethyl]-3-Pyrrolidinyl}-2,2-Diphenylacetamide Hydrobromide HBr

Manufacturer: Novartis & Pfizer Oct.28.2004—European Commission has granted Marketing Authorization Emselex for the treatment of overactive. Dec.23.2004—FDA has approved darifenacin HBr for the treatment of OAB.

The structure-activity relationship Part A imidazole ring being replaced by alkyl will significantly affect anti-cholinergic receptor activity and selectivity; Part B for the connecting part, usually two carbon anticholinergic activity at best. carbon chain growes, activity will decrease;

The structure-activity relationship Part C of the amide or H atom, anticholinergic activity and M3 receptor selectivity better, N-monosubstituted, N, N-disubstituted or ester is anticholinergic activity decreases even without anticholinergic activity.

The structure-activity relationship Part D benzene generally no replaced if heterocyclic or alkyl replace it activity decreases, one of benzene may be replaced by six atom ring : Oxybutynin.

Synthesis:

Pharmacodynamics of darifenacin

Darifenacin Darifenacin is a competitive muscarinic receptor antagonist labeled for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Mechanism of OAB The symptoms of OAB are thought to result from involuntary contractions of the detrusor muscle during the bladder filling phase.

Receptors in bladder tissue M2,M3 muscarinic receptors with a ratio of 3:1 exist in human bladder tissue. Although the density of M2 receptors is much greater than that of the M3 subtype, M3 receptor subtype is predominant in the mediation of bladder contraction.

M3 receptor M3 are responsible for urinary bladder contraction,gastrointestinal smooth muscle contraction, saliva production, and iris sphincter regulation.

Mechanism of Action Darifenacin has been shown to have high affinity and selectivity for the muscarinic M3 receptor, with low selectivity for the other muscarinic receptor subtypes.

Effect Help to reduce the incidence of urinary incontinence . Increase urinary bladder reserves . Reduce the frequency of urination. Reduce the oppressive sense of eager to urinate and urinary urgency sense.

dry mouth constipation blurred vision heat prostration others side effects dry mouth constipation blurred vision heat prostration others

Pharmacokinetic properties Darifenacin is metabolised by CYP3A4 and CYP2D6.

CYP3A4 CYP2D6

Absorption

ENABLEX® 7.5 mg (N = 68 EM, 5 PM) ENABLEX®15 mg (N = 102 EM, 17 PM) AUC24 (ng.h/mL) Cmax (ng/mL) Cavg (ng/mL) Tmax (h) t1/2 (h) EM 29.24 (15.47) 2.01 (1.04) 1.22 (0.64) 6.49 (4.19) 12.43 (5.64) a 88.90 (67.87) 5.76 (4.24) 3.70 (2.83) 7.61 (5.06) 12.05 (12.37) b PM 67.56 (13.13) 4.27 (0.98) 2.81 (0.55) 5.20 (1.79) 19.95 c 157.71 (77.08) 9.99 (5.09) 6.58 (3.22) 6.71 (3.58) 7.40 d

Distribution lipophilic base 98% bound to plasma proteins Vss =163 litres

Metabolism Darifenacin metabolism (oral administration) CYP3A4 CYP2D6 in the liver CYP3A4 in the gut wall

three main metabolic routes monohydroxylation in the dihydrobenzofuran ring dihydrobenzofuran ring opening N-dealkylation of the pyrrolidine nitrogen

CYP3A4

CYP2D6

CYP2D6/CYP3A4

Excretion Following administration of an oral dose of 14C-darifenacin solution to healthy volunteers, approximately 60% of the radioactivity was recovered in the urine and 40% in the faeces. Only a small percentage of the excreted dose was unchanged darifenacin (3%).

Comparison of Darifenacin with Other Antimuscarinics

Efficacy against urinary frequency

NICE states that : there is NO evidence of clinically important efficacy differences among antimuscarinic drugs

Adverse events

Selected adverse events

Selection of antimuscarinic drug for treatment of OAB

NICE states that : Non-proprietary, immediate-release oxybutynin, which is the most cost-effective of the available options, should be offered as first-line antimuscarinic if bladder training is ineffective. If not tolerated, darifenacin, solifenacin, tolterodine, trospium or an extended-release or transdermal formulations of oxybutynin should be considered.

MEMBERS 0440101 Cui Sisi 0440118 Wang Lutai 0441707 Lu Lisha 0440220 Wang Yan 0440211 Gao Wei

THANK YOU!